Pei Ye

Title: Pei Ye: Innovator in Antibody Development

Introduction

Pei Ye is a prominent inventor based in Lawrenceville, GA (US). He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 4 patents, his work focuses on enhancing the efficacy of treatments for various cancers.

Latest Patents

Pei Ye's latest patents include a groundbreaking humanized anti-CD20 antibody. This invention features an antigen binding site that incorporates the heavy and light chains of obinutuzumab (GAZYVA®). The antibody is designed with N-linked oligosaccharides attached to the Fc region, which are not bisected by N-acetylglucosamine. Notably, the anti-CD20 antibody exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) that is approximately two times stronger than GAZYVA® and 50 to 100 times stronger than RITUXAN®. This innovation is particularly effective for treating CD20 expressing cancers, including non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, and follicular lymphoma.

Career Highlights

Pei Ye is currently associated with Beijing Mabworks Biotech Co. Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key player in the biotechnology sector, contributing to the development of therapies that can significantly improve patient outcomes.

Collaborations

Pei Ye collaborates with notable colleagues, including Feng Li and Boyan Zhang. These partnerships enhance the innovative capacity of his research and contribute to the success of their projects.

Conclusion

Pei Ye's contributions to the field of biotechnology, particularly through his innovative anti-CD20 antibody, highlight his role as a leading inventor. His work not only advances scientific knowledge but also has the potential to improve treatment options for patients with cancer.